160
Participants
Start Date
November 30, 2007
Primary Completion Date
February 28, 2013
Study Completion Date
February 28, 2013
ACC-001 + QS-21
IM injection, ACC-001 (3ug, or 10ug, or 30ug) + QS-21 50ug at Day 1 and weeks 4, 12, 26, and 52
QS-21
IM injection, QS-21 (50 ug) at Day 1 and weeks 4, 12, 26, and 52
Diluent: Phosphate Buffered Saline
IM injection, PBS Diluent at Day 1 and weeks 4, 12, 26, and 52
ACC-001
IM injection, ACC 001 (10 ug, 30ug) at Day 1 and weeks 4, 12, 26, and 52
Columbia Univ/Taub Institute Irving Ctr for Clinical Researc, New York
CUMC Research Pharmacy, New York
General Clinical Research Center, Washington D.C.
GUMC, Washington D.C.
MD Clinical, Hallandale
Palm Beach Neurology - Premiere Research Institute, West Palm Beach
Barnes-Jewish Hospital, St Louis
Washington University School of Medicine, St Louis
Barrnes-Jewish Hospital at Washington University, St Louis
Washington University School of Medicine, St Louis
Banner Alzheimer's Institute, Phoenix
Banner Good Samaritan Medical Center, Phoenix
Banner Boswell Medical Center, Sun City
Sun Health Research Institute, Sun City
University of California - San Francisco, San Francisco
University of California, San Francisco, San Francisco
University of California, San Francisco, San Francisco
University of California, San Francisco, San Francisco
General Clinical Research Center, New Haven
Yale University School of Medicine, New Haven
Yale-New Haven Hospital, New Haven
Brigham and Women's Hospital, Boston
Memory Enhancement Center of America, Inc., Eatontown
Pharmcare USA, Edison
Butler Hospital, Providence
The Memory Clinic, Bennington
The Pharmacy, Bennington
Lead Sponsor
JANSSEN Alzheimer Immunotherapy Research & Development, LLC
INDUSTRY
Pfizer
INDUSTRY